推荐产品
一般說明
Human metapneumovirus (hMPV) is a member of the pneumovirinae subfamily of paramyxoviruses, first described in 2001 from pediatric respiratory specimens in the Netherlands. It is an enveloped pleomorphic virus with a single negative-strand RNA genome. Two major serotypes, A and B, have been described. Several studies identified hMPV in specimens worldwide, and estimated that by age 5 years 70% of children have developed antibodies to hMPV.
應用
Anti-Human Metapneumovirus Antibody, clone 132 is an antibody against Human Metapneumovirus for use in ELISA, FC & IF.
外觀
Format: Purified
其他說明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法律資訊
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our 产品选型工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Xiao Xiao et al.
Nature communications, 13(1), 2546-2546 (2022-05-11)
Human metapneumovirus (hMPV) belongs to the Pneumoviridae family and is closely related to respiratory syncytial virus (RSV). The surface fusion (F) glycoprotein mediates viral fusion and is the primary target of neutralizing antibodies against hMPV. Here we report 113 hMPV-F
Xiao Xiao et al.
Journal of virology, 97(12), e0105223-e0105223 (2023-11-30)
Human metapneumovirus (hMPV) is a common pathogen causing lower respiratory tract infections worldwide and can develop severe symptoms in high-risk populations such as infants, the elderly, and immunocompromised patients. There are no approved hMPV vaccines or neutralizing antibodies available for
Aimin Tang et al.
Nature communications, 10(1), 4153-4153 (2019-09-14)
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation
Charles J Russell et al.
Virology, 509, 60-66 (2017-06-13)
Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production
Xiao Xiao et al.
mAbs, 11(8), 1415-1427 (2019-08-14)
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children and older adults. Currently, no licensed vaccine is available, and therapeutic options are limited. The primary target of neutralizing antibodies to RSV is the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门